NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.65 (+0.71%)

Growth Price

Overvalued by 26.88%

Stability Price

Overvalued by 73.39%

Company Metrics

  • 23.35 P/E
  • 3.76 P/S
  • 3.17 P/B
  • 3.938 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 2.96% Dividend
  • 1.36M Avg. Vol.
  • 224.7B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Novartis Sells Its Low-Margin Influenza Vaccine Business
Bidness ETC - Oct 27, 2014
Novartis AG (ADR) (NVS) announced before US markets opened for Monday's trading session that it has agreed to sell its “global influenza vaccine business,” including the company's pipeline development products, to Australia-based biotech CSL Ltd.
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Bidness ETC - Oct 28, 2014
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Novartis Announces Positive Phase-III Results For Secukinumab
Bidness ETC - Oct 23, 2014
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
FDA Advisory Committee Votes In Favor Of Novartis' IL-17 Inhibitor
Bidness ETC - Oct 21, 2014
Novartis AG (ADR) (NVS) announced yesterday that the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA has unanimously recommended the use of Novartis' AIN457 in adults who are suffering from moderate-to-severe plaque psoriasis.
Stocks in Focus- Bristol-Myers Squibb Co (NYSE:BMY), Novartis AG (ADR ...
StreetWise Report - Oct 24, 2014
Novartis AG (ADR) (NYSE:NVS) declared that the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has mutually voted in favor of admiring AIN457 a selective interleukin-17A inhibitor for the treatment of moderate to severe plaque psoriasis in ...
Watch List Highlights - Novartis AG (ADR) (NYSE:NVS), Receptos Inc (NASDAQ ...
Street Newswire (registration) - Oct 28, 2014
Novartis AG (ADR) (NYSE:NVS), the global pharmaceuticals company posted Q3 earnings and sales that topped estimates.
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
StreetWise Report - Oct 13, 2014
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Pharma Stocks To Look Out For This Week
Bidness ETC - Oct 13, 2014
The US Food and Drug Administration (FDA) is also expected to release briefs for the Advisory Committee's meeting next week to give recommendations on Novartis AG (ADR)'s (NVS) secukinumab and Vertex Pharmaceuticals Incorporated's (VRTX) ...
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Street Newswire - Oct 8, 2014
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Techsonian (press release) - Sep 30, 2014
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...